LENSAR (LNSR) Aandelenoverzicht
LENSAR, Inc. is een bedrijf dat zich toelegt op het ontwerpen, ontwikkelen en commercialiseren van lasersystemen voor de behandeling van cataract en het beheer van reeds bestaand of chirurgisch veroorzaakt hoornvliesastigmatisme in de Verenigde Staten, Europa, Azië, Zuid-Korea en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 4/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
LNSR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
LENSAR, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$5.71 |
| 52 Week Hoogtepunt | US$13.47 |
| 52 Week Laag | US$5.06 |
| Bèta | 0.87 |
| 1 maand verandering | -1.55% |
| 3 maanden verandering | -4.36% |
| 1 Jaar Verandering | -55.36% |
| 3 jaar verandering | 28.31% |
| 5 jaar verandering | -32.02% |
| Verandering sinds IPO | -36.56% |
Recent nieuws en updates
LNSR: Recent Upgrade And Margin Outlook Will Drive Repricing Potential
Analysts have maintained their $8.50 price target on LENSAR, citing a modestly lower discount rate and slightly adjusted long term margin and P/E assumptions following a recent upgrade in Street research coverage. What's in the News On April 10, 2026, LENSAR reported that Chief Financial Officer Thomas R.LNSR: Post Deal Selloff Will Set Up Margin Led Repricing Potential
Analysts have lifted their price target on LENSAR to $10, citing stronger profit margin expectations, a lower assumed discount rate, and a reduced future P/E, even as projected revenue growth is now more conservative. Analyst Commentary Bullish Takeaways Bullish analysts highlight the $10 price target as reflecting confidence that LENSAR's expected profit margins can support a higher valuation multiple than previously assumed.LNSR: Buy Thesis Will Rebuild Around Post Deal Selloff And Adoption Reacceleration
Analysts have nudged their price target on LENSAR stock to $8.50, with recent upgrades to Buy and renewed confidence around the ALLY System adoption story cited as key reasons for the updated view. Analyst Commentary Recent research has focused on how the ALLY System adoption story and the fallout from the halted Alcon acquisition are shaping expectations for LENSAR’s execution and valuation.Recent updates
LNSR: Recent Upgrade And Margin Outlook Will Drive Repricing Potential
Analysts have maintained their $8.50 price target on LENSAR, citing a modestly lower discount rate and slightly adjusted long term margin and P/E assumptions following a recent upgrade in Street research coverage. What's in the News On April 10, 2026, LENSAR reported that Chief Financial Officer Thomas R.LNSR: Post Deal Selloff Will Set Up Margin Led Repricing Potential
Analysts have lifted their price target on LENSAR to $10, citing stronger profit margin expectations, a lower assumed discount rate, and a reduced future P/E, even as projected revenue growth is now more conservative. Analyst Commentary Bullish Takeaways Bullish analysts highlight the $10 price target as reflecting confidence that LENSAR's expected profit margins can support a higher valuation multiple than previously assumed.LNSR: Buy Thesis Will Rebuild Around Post Deal Selloff And Adoption Reacceleration
Analysts have nudged their price target on LENSAR stock to $8.50, with recent upgrades to Buy and renewed confidence around the ALLY System adoption story cited as key reasons for the updated view. Analyst Commentary Recent research has focused on how the ALLY System adoption story and the fallout from the halted Alcon acquisition are shaping expectations for LENSAR’s execution and valuation.LNSR: Buy Thesis Rebuilds Around Post Deal Selloff And Adoption Reacceleration
Analysts have raised their price targets on LENSAR shares to $10, citing renewed optimism around ALLY System adoption and viewing the post acquisition setback selloff as a second chance for investors. Analyst Commentary Bullish Takeaways Bullish analysts point to a $10 price target as a simple yardstick for how they frame upside potential if ALLY System adoption trends seen before the Alcon deal announcement can be re established.
Cataract Procedure Bundling Will Pressure Margins Yet Recurring Revenue Should Support Gradual Recovery
Catalysts About LENSAR LENSAR develops and commercializes robotic femtosecond laser systems for cataract surgery, with a focus on its ALLY Robotic Laser Cataract System. What are the underlying business or industry changes driving this perspective?LNSR: Buy Rating Resets Around Post Deal Selloff And Execution Rebuild
Analysts have trimmed their price target for LENSAR to $8.50 from $12.50, reflecting updated views on revenue growth, profitability and a lower future P/E, while also pointing to recent upgrades that highlight renewed interest in the stock following the failed Alcon acquisition. Analyst Commentary Recent Street research has focused on the reset expectations for LENSAR following the failed Alcon transaction, as well as the potential runway for the company’s ALLY System.
Recurring Cataract Procedure Revenue And Machine Learning Will Transform This Undervalued Medical Device Story
Catalysts About LENSAR LENSAR develops and commercializes the ALLY Robotic Laser Cataract System for laser assisted cataract surgery. What are the underlying business or industry changes driving this perspective?LNSR: Buy Rating And Post Deal Reset Will Drive Future Reassessment
Analysts have trimmed their fair value estimate for LENSAR from $15.00 to $12.50, pointing to revised assumptions around discount rates, margins, and future P/E, alongside a BTIG upgrade to Buy that highlights past ALLY System adoption and the recent post acquisition selloff as a potential second chance for investors to reassess the story. Analyst Commentary Bullish Takeaways Bullish analysts highlight that the cut in fair value to $12.50 still sits above the current $10 price target.Global System Placements Will Improve Operating Room Efficiency
Strong system placements and contract pipelines in international markets enhance potential for sustained revenue growth and competitive advantage.Even With A 28% Surge, Cautious Investors Are Not Rewarding LENSAR, Inc.'s (NASDAQ:LNSR) Performance Completely
Despite an already strong run, LENSAR, Inc. ( NASDAQ:LNSR ) shares have been powering on, with a gain of 28% in the...We're Hopeful That LENSAR (NASDAQ:LNSR) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, LENSAR...Market Might Still Lack Some Conviction On LENSAR, Inc. (NASDAQ:LNSR) Even After 28% Share Price Boost
LENSAR, Inc. ( NASDAQ:LNSR ) shareholders would be excited to see that the share price has had a great month, posting a...LENSAR (NASDAQ:LNSR) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...LENSAR, Inc. (NASDAQ:LNSR) Doing What It Can To Lift Shares
With a price-to-sales (or "P/S") ratio of 1.3x LENSAR, Inc. ( NASDAQ:LNSR ) may be sending bullish signals at the...Here's Why Shareholders May Want To Be Cautious With Increasing LENSAR, Inc.'s (NASDAQ:LNSR) CEO Pay Packet
Key Insights LENSAR to hold its Annual General Meeting on 7th of May Salary of US$541.1k is part of CEO Nick Curtis's...LENSAR, Inc.'s (NASDAQ:LNSR) Shares Leap 33% Yet They're Still Not Telling The Full Story
LENSAR, Inc. ( NASDAQ:LNSR ) shares have continued their recent momentum with a 33% gain in the last month alone...Here's Why We're Watching LENSAR's (NASDAQ:LNSR) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Not Many Are Piling Into LENSAR, Inc. (NASDAQ:LNSR) Just Yet
LENSAR, Inc.'s ( NASDAQ:LNSR ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong buy right now...Here's Why We're A Bit Worried About LENSAR's (NASDAQ:LNSR) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...Investors Continue Waiting On Sidelines For LENSAR, Inc. (NASDAQ:LNSR)
LENSAR, Inc.'s ( NASDAQ:LNSR ) price-to-sales (or "P/S") ratio of 0.9x might make it look like a strong buy right now...This Broker Just Slashed Their LENSAR, Inc. (NASDAQ:LNSR) Earnings Forecasts
One thing we could say about the covering analyst on LENSAR, Inc. ( NASDAQ:LNSR ) - they aren't optimistic, having just...Will LENSAR (NASDAQ:LNSR) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Here's Why We're Not Too Worried About LENSAR's (NASDAQ:LNSR) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...LENSAR GAAP EPS of -$0.67, revenue of $8M
LENSAR press release (NASDAQ:LNSR): Q2 GAAP EPS of -$0.67. Revenue of $8M (+1.3% Y/Y). Adjusted EBITDA was -$4.3M for the quarter ended June 30, 2022 and -$2.3M for the quarter ended June 30, 2021. As of June 30, 2022, the company had cash and cash equivalents of $25.2M as compared to $31.6M at December 31, 2021. Based on its cash position and operational forecasts, the company believes it has sufficient cash to fund operations into 2024.Rendement voor aandeelhouders
| LNSR | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | -0.2% | 4.6% | 0.3% |
| 1Y | -55.4% | -21.2% | 19.9% |
Rendement versus industrie: LNSR presteerde slechter dan de US Medical Equipment -sector, die het afgelopen jaar een rendement van -21.2 % opleverde.
Rendement versus markt: LNSR presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 19.9 % opleverde.
Prijsvolatiliteit
| LNSR volatility | |
|---|---|
| LNSR Average Weekly Movement | 7.7% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: LNSR heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van LNSR is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2004 | 150 | Nick Curtis | www.lensar.com |
LENSAR, Inc. is een commercieel bedrijf gespecialiseerd in medische apparatuur dat zich toelegt op het ontwerp, de ontwikkeling en de marketing van lasersystemen voor de behandeling van cataract en de behandeling van reeds bestaand of chirurgisch veroorzaakt hoornvliesastigmatisme in de Verenigde Staten, Europa, Azië, Zuid-Korea en internationaal. Het bedrijf biedt het LENSAR lasersysteem aan, dat een reeks gepatenteerde technologieën bevat die ontworpen zijn om de chirurg te helpen bij het verkrijgen van visuele resultaten door middel van beeldvorming, procedureplanning, ontwerp en precisie. LENSAR biedt ook het ALLY Robotic Cataract Laser System aan, een compact systeem voor cataractbehandeling waarmee chirurgen steriele cataractoperaties met behulp van een laser kunnen uitvoeren in één enkele operatiekamer.
LENSAR, Inc. Samenvatting
| LNSR fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$69.24m |
| Inkomsten(TTM) | US$29.40m |
| Inkomsten(TTM) | US$57.70m |
Is LNSR overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| LNSR resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$57.70m |
| Kosten van inkomsten | US$31.33m |
| Brutowinst | US$26.38m |
| Overige uitgaven | -US$3.02m |
| Inkomsten | US$29.40m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 2.43 |
| Brutomarge | 45.71% |
| Nettowinstmarge | 50.94% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde LNSR op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/30 21:29 |
| Aandelenkoers aan het einde van de dag | 2026/06/30 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
LENSAR, Inc. wordt gevolgd door 3 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Michael Gorman | BTIG |
| Frank Takkinen | Lake Street Capital Markets, LLC |
| Richard Newitter | Leerink Partners LLC |